SCHEMBL446930

SCHEMBL446930

CC(=O)OC(=O)[C@@H](N)CCCNC(=N)N

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPY4R P50391 8/20 0.39
NPY1R P25929 5/20 0.39
DPP7 Q9UHL4 2/20 0.38
ALOX15 P16050 1/20 0.37
NPY2R P49146 4/20 0.36
NPY5R Q15761 4/20 0.36
OTC P00480 1/20 0.35
GNAI3 P08754 1/20 0.34
GNAO1 P09471 1/20 0.34
GNAI1 P63096 1/20 0.34
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
DDAH1 O94760 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
RRM1 P23921 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25300066 1.00 NPY4R (0.39) NPY4RNPY1RDPP7ALOX15NPY2R
SCHEMBL5970619 1.00 NPY4R (0.39) NPY4RNPY1RDPP7ALOX15NPY2R
Hydrochloric Acid SCHEMBL4422483 0.98 NPY4R (0.38) NPY4RNPY1RDPP7ALOX15NPY2R
SCHEMBL4443243 0.98 NPY4R (0.38) NPY4RNPY1RDPP7ALOX15NPY2R
SCHEMBL8911027 0.98 NPY4R (0.38) NPY4RNPY1RDPP7ALOX15NPY2R
SCHEMBL9237239 0.90 NPY4R (0.39) NPY4RNPY1RDPP7ALOX15NPY2R
SCHEMBL288133 0.90 NPY4R (0.39) NPY4RNPY1RDPP7ALOX15NPY2R
SCHEMBL28712062 0.90 NPY4R (0.39) NPY4RNPY1RDPP7ALOX15NPY2R
SCHEMBL16194087 0.89 NPY4R (0.38) NPY4RNPY1RDPP7ALOX15NPY2R
Hydrochloric Acid SCHEMBL8039440 0.89 NPY4R (0.38) NPY4RNPY1RDPP7ALOX15NPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 919 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3930666-B1 ORAL CARE PRODUCT COLGATE PALMOLIVE CO (US) 2026-05-27 EP claimed
EP-4731755-A2 COMPOSITIONS AND METHODS FOR REDUCING HOST CELL PROTEINS IN RECOMBINANT ADENO-ASSOCIATED VIRUS PREPARATIONS Ultragenyx Pharmaceutical Inc. (US) 2026-04-29 EP claimed
US-12599669-B2 Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations AMGEN INC. (US) 2026-04-14 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
EP-4634201-A1 ARGININE WASH IN PROTEIN PURIFICATION H. Lundbeck A/S (DK) 2025-10-22 EP claimed
EP-4588932-A2 PREPARATION OF FACTOR XA DERIVATIVES ALEXION PHARMACEUTICALS, INC. (US) 2025-07-23 EP claimed
US-20250213449-A1 Oral Care Product And Methods Of Use And Manufacture Thereof COLGATE-PALMOLIVE COMPANY (US) 2025-07-03 US claimed
EP-4565608-A2 PHARMACEUTICAL COMPOSITIONS OF FUSION PROTEINS AND METHODS OF USE THEREOF Alexion Pharmaceuticals, Inc. (US) 2025-06-11 EP claimed
CN-120022522-A Drug-loaded microneedle, drug-loaded microneedle patch and electrically-controlled drug release microneedle system 成都邦迈医创科技有限公司 2025-05-23 CN claimed
CN-116425860-B Preparation of factor XA derivatives 阿雷克森制药公司 2025-03-04 CN claimed
US-20040176321-A1 Compositions of benzoquinolizine carboxylic acid antibiotic drugs WOCKHARDT LIMITED 2004-09-09 US claimed
WO-2004058303-A2 COMPOSITIONS OF BENZOQUINOLIZINE CARBOXYLIC ACID ANTIBIOTIC DRUGS WOCKHARDT LIMITED (IN) 2004-07-15 WO claimed
CN-1465341-A Arginine acetate oral preparation and clinical application thereof 王兰周 2004-01-07 CN claimed
US-5686416-A BRADYKININ ANALOGUES; NONA-, DECA- AND POLYPEPTIDES ALKERMES, INC. (US) 1997-11-11 US claimed
US-5350766-A Method for the prevention and/or palliation of the complications of diabetes using N-alpha orginine acetyl NEW YORK MEDICAL COLLEGE (US) 1994-09-27 US claimed
EP-0189941-B1 ANTIBIOTIC COMPOSITIONS Bristol-Myers Squibb Company (US) 1990-09-26 EP claimed
US-4876688-A CONTAINING A CHIRAL CARBON THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECETARY OF THE DEPARTMENT OF ENERGY (US) 1989-10-24 US claimed
EP-0140027-B1 AQUEOUS SOLUTION FOR COOLING COLD-ROLLED STEEL STRIP IN A CONTINUOUS ANNEALING PROCESS NIPPON STEEL CORPORATION (JP) 1989-07-05 EP claimed
EP-0189941-A2 Antibiotic compositions Bristol-Myers Squibb Company (US) 1986-08-06 EP claimed
US-4561911-A CONTAINING AMINO ACID NIPPON STEEL CORPORATION (JP) 1985-12-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule CD4, TAP1, MCTS1 NPY4R 3868/4885NPY1R 2318/4885DPP7 1167/4885
US-20040176321-A1 Compositions of benzoquinolizine carboxylic acid antibiotic drugs H1-5, DDC, HRH1 NPY4R 504/4885NPY1R 245/4885DPP7 264/4885
US-12599669-B2 Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations PNISR, ALB, ACP1 NPY4R 808/4885NPY1R 951/4885DPP7 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.